Medicare Patient IVIG Access Act of 2009

HR 1765: To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intraveneous immune globulin (IVIG) in a patient's home for the treatment of primary immunde deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. HR 5597: To establish a Medicare patient IVIG access demonstration project HR 4994-Medicare and Medicaid Extenders Act of 2010: To establish a Medicare patient IVIG access demonstration project S 701-Medicare Patient IVIG Access Act of 2009 HR 1586-Education, Jobs and Medicaid funding bill as it relates to Medicaid AMP

Client expense: $581,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, State, Dept of (DOS)

S.701-Medicare Patient IVIG Access Act of 2009 H.R.1765-To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program H.R.5597-To establish a Medicare patient IVIG access demonstration project

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Various issues surrounding health care reform. HR 3200, HR 1339, S 1235, HR 1392, S 1221, HR 3590, HR 1188, S 468, HR 1765, HR 4827, S.701, HR 4985, H.RES 1444, HR 5597, HR 2400, HR 1549, HR 5106.

Client expense: Not reported · Firm income: $110,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S. 701 Medicare Patient IVIG Access Act of 2009 HR 1765, Medicare Home Infusion Legislation HR 1085/ s 442 Health Insurance Coverage Protection Act HR 3590 Patient Protection and Affordable Care Act HR 3962 Affordable Healthcare for America Act

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), SENATE

Medicare Patient IVIG Access Act (S. 701) H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, Health Care and Education Reconciliation Act, provisions concerning orphan drugs; H.R. 4813, to provide for insurance reform, provisions concerning orphan drugs.

Client expense: Not reported · Firm income: $40,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of

H.R.1765: To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. H.R. 5597: To establish a Medicare patient IVIG access demonstration project S.701: Medicare Patient IVIG Access Act of 2009 H.R. 1586: Education, Jobs and Medicaid funding bill as it relates to Medicaid AMP

Client expense: $930,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Economic Council (NEC), SENATE, State, Dept of (DOS)

Medicare and Medicaid reimbursement issues for certain drugs and biologicals; all issues related to Medicare coverage of pre-ESRD education. S. 701 / H.R. 2002, Medicare IVIG Access Act as it relates to Medicare coverage of IVIG services. H.R. 1765, as it relates to Medicare coverage and payment for IVIG administered in the home. H.R. 5597, To establish a Medicare patient IVIG access demonstration project. H.R. 4213, The Tax Extenders Act as it relates to access to IVIG for Medicare beneficiaries. S. 525, S. 1232 / H.R. 1298, the Pharmaceutical Market Access & Drug Safety Act, as it relates to the importation of biologicals and pedigree. Drug safety issues, including H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree.

Client expense: Not reported · Firm income: $57,500

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Medicare and Medicaid reimbursement issues for certain drugs and biologicals; all issues related to Medicare coverage of pre-ESRD education. H.R. 2002 / S. 701, Medicare Patient IVIG Access Act as it relates to Medicare coverage of IVIG services. H.R. 1765, as it relates to Medicare coverage & payment for IVIG administered in the home. H.R. 5597, To establish a Medicare patient IVIG access demonstration project. H.R. 4213, The Tax Extenders Act, as it relates to access to IVIG for Medicare beneficiaries.

Client expense: Not reported · Firm income: $57,500

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Medicare Patient IVIG Access Act (S. 701) H.R. 3590, Patient Protection and Affordable Care Act, provisions regarding pharmaceutical fees; H.R. 4872, Health Care and Education Reconciliation Act, provisions concerning Medicaid rebates, orphan drugs; H.R. 4813, to provide for insurance reform, provisions concerning Medicaid rebates, orphan drugs.

Client expense: $70,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS), SENATE, Treasury, Dept of

Medicare Patient IVIG Access Act (S. 701) H.R. 3590, Patient Protection and Affordable Care Act, provisions regarding pharmaceutical fees; H.R. 4872, Health Care and Education Reconciliation Act, provisions concerning Medicaid rebates, orphan drugs; H.R. 4813, to provide for insurance reform, provisions concerning Medicaid rebates, orphan drugs.

Client expense: $70,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS), SENATE, Treasury, Dept of

Medicare Patient IVIG Access Act (S. 701) H.R. 3590, Patient Protection and Affordable Care Act, provisions regarding pharmaceutical fees; H.R. 4872, Health Care and Education Reconciliation Act, provisions concerning Medicaid rebates, orphan drugs; H.R. 4813, to provide for insurance reform, provisions concerning Medicaid rebates, orphan drugs.

Client expense: $70,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS), SENATE, Treasury, Dept of

HR 1765: Medicare IVIG Home Infusion Legislation HR 1392: Medicare Part B Prompt-Pay Legislation S 701: "Medicare Patient IVIG Access Act of 2009" HR 2002: Medicare Patient IVIG Access Act HR 5597: Medicare Patient IVIG Access Demonstration project S 1221: A bill to amend title XVIII of the Social Security Act to ensure more appropriate payment amounts for drugs and biologicals under part B of the Medicare Program by excluding customary prompt pay discounts extended to wholesalers from the manufacturer's average sales price.

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S 701: Medicare Patient IVIG Access Act of 2009 HR 1765: Medicare IVIG Home Infusion Legislation HR 2002: Medicare Patient IVIG Access Act HR 5597: Medicare Patient IVIG Access Demonstration Project HR 4213: The American Jobs and Closing Tax Loopholes Act (340B Program inpatient expansion) Pharmaceutical Industry Annual Fee; Orphan Drug Exclusion

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

HR 1765: Medicare IVIG Home Infusion Legislation HR 1392: Medicare Part B Prompt-Pay Legislation S 701: "Medicare Patient IVIG Access Act of 2009" HR 2002: Medicare Patient IVIG Access Act HR 5597: Medicare Patient IVIG Access Demonstration project S 1221: A bill to amend title XVIII of the Social Security Act to ensure more appropriate payment amounts for drugs and biologicals under part B of the Medicare Program by excluding customary prompt pay discounts extended to wholesalers from the manufacturer's average sales price.

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Various issues surrounding health care reform. HR 3200, HR 1339, S 1235, HR 1392, S 1221, HR 3590, HR 1188, S 468, HR 1765, HR 4827, S.701, HR 4985, H.RES 1444, HR 5597, HR 2400, HR 1549, HR 5106.

Client expense: Not reported · Firm income: $70,000

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE

S. 701 Medicare Patient IVIG Access Act of 2009 HR 1765, Medicare Home Infusion Legislation HR 1085/ s 442 Health Insurance Coverage Protection Act HR 3590 Patient Protection and Affordable Care Act HR 3962 Affordable Healthcare for America Act

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), SENATE

Medicare Patient IVIG Access Act (S. 701); H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, Health Care and Education Reconciliation Act, provisions concerning Medicaid rebates, orphan drugs; H.R. 4813, to provide for insurance reform, provisions concerning Medicaid rebates, orphan drugs.

Client expense: Not reported · Firm income: $40,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of

Medicare and Medicaid reimbursement issues for certain drugs and biologicals; all issues related to Medicare coverage of pre-ESRD education. S. 701 / H.R. 2002, Medicare IVIG Access Act as it relates to Medicare coverage of IVIG services. H.R. 1765, as it relates to Medicare coverage and payment for IVIG administered in the home. H.R. 5597, To establish a Medicare patient IVIG access demonstration project. H.R. 4213, The Tax Extenders Act as it relates to access to IVIG for Medicare beneficiaries. S. 525, S. 1232 / H.R. 1298, the Pharmaceutical Market Access & Drug Safety Act, as it relates to the importation of biologicals and pedigree. H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree.

Client expense: Not reported · Firm income: $57,500

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Medicare and Medicaid reimbursement issues for certain drugs and biologicals; all issues related to Medicare coverage of pre-ESRD education. H.R. 2002 / S. 701, Medicare Patient IVIG Access Act as it relates to Medicare coverage of IVIG services. H.R. 1765, as it relates to Medicare coverage & payment for IVIG administered in the home. H.R. 5597, To establish a Medicare patient IVIG access demonstration project. H.R. 4213, The Tax Extenders Act, as it relates to access to IVIG for Medicare beneficiaries.

Client expense: Not reported · Firm income: $57,500

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

H.R. 3200: To provide affordable, quality health care for all Americans and reduce the growth in health care spending. H.R. 4872: The Health Care and Education Reconciliation Act. S. 301: A bill to amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid or SCHIP. H.R.1765: To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. H.R. 5597: To establish a Medicare patient IVIG access demonstration project H.R. 4899: Small Business and Infrastructure Jobs Tax Act of 2010, specific focus on Average Manufacturer Price (AMP) calculation for Medicaid drugs. H.R. 4213: American Jobs and Closing Tax Loopholes Act of 2010, specific focus on Average Manufacturer Price (AMP) calculation for Medicaid drugs, changes to 340B drug discount program and international tax provisions and research and development tax credits. H.R. 4846: Bleeding Disorder Screening, Awareness, and Further Education (SAFE) Act of 2010 S.701: A bill to amend title XVIII of the Social Security Act to improve access of Medicare beneficiaries to intravenous immune globulins (IVIG). S. 1796/H.R. 3200: America's Healthy Future Act, as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices.

Client expense: $950,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Economic Council (NEC), SENATE, State, Dept of (DOS)

S 701: Medicare Patient IVIG Access Act of 2009 HR 1765: Medicare IVIG Home Infusion Legislation HR 2002: Medicare Patient IVIG Access Act HR 5597: Medicare Patient IVIG Access Demonstration Project HR 4213: The American Jobs and Closing Tax Loopholes Act (340B Program inpatient expansion) Pharmaceutical Industry Annual Fee; Orphan Drug Exclusion

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

HR 1765: Medicare IVIG Home Infusion Legislation HR 1392: Medicare Part B Prompt-Pay Legislation S 701: "Medicare Patient IVIG Access Act of 2009" HR 2002: Medicare Patient IVIG Access Act HR 5597: Medicare Patient IVIG Access Demonstration project

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Medicare Patient IVIG Access Act (S. 701); H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, Health Care and Education Reconciliation Act, provisions concerning Medicaid rebates, orphan drugs; H.R. 4813, to provide for insurance reform, provisions concerning Medicaid rebates, orphan drugs.

Client expense: $70,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of

Various issues surrounding health care reform. HR 3200, HR 1339, S 1235, HR 1392, S 1221, HR 3590, HR 1188, S 468, HR 1765, HR 4827, S.701,

Client expense: Not reported · Firm income: $70,000

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE

S. 701 Medicare Patient IVIG Access Act of 2009 HR 1765, Medicare Home Infusion Legislation HR 1085/ s 442 Health Insurance Coverage Protection Act HR 3590 Patient Protection and Affordable Care Act HR 3962 Affordable Healthcare for America Act

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), SENATE

Medicare Patient IVIG Access Act (S. 701); H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, Health Care and Education Reconciliation Act, provisions concerning Medicaid rebates, orphan drugs; H.R. 4813, to provide for insurance reform, provisions concerning Medicaid rebates, orphan drugs.

Client expense: Not reported · Firm income: $30,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Medicare and Medicaid reimbursement issues for certain drugs and biologicals; all issues related to Medicare coverage of pre-ESRD education. S. 701, Medicare IVIG Access Act as it relates to Medicare coverage of IVIG services. H.R. 1765, as it relates to Medicare coverage and payment for IVIG administered in the home. H.R. 3200, America's Affordable Health Choices Act of 2009, H.R. 3590, The Patient Protection and Affordable Health Care Act, H.R. 3962, Affordable Health Care for America Act, H.R. 4872, the Health Care and Education Reconciliation Act of 2010, as they relate to fees on manufacturers of drugs & medical devices, Medicaid rebates, Medicare reimbursement for drugs & access to IVIG for Medicare beneficiaries, and taxation of employer-sponsored health coverage. S. 525, S. 1232 / H.R. 1298, the Pharmaceutical Market Access & Drug Safety Act, as it relates to the importation of biologicals and pedigree. H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree.

Client expense: Not reported · Firm income: $57,500

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Medicare and Medicaid reimbursement issues for certain drugs and biologicals; all issues related to Medicare coverage of pre-ESRD education. H.R. 2002 / S. 701, Medicare Patient IVIG Access Act as it relates to Medicare coverage of IVIG services. H.R. 1765, as it relates to Medicare coverage & payment for IVIG administered in the home. H.R. 3200, America's Affordable Health Choices Act of 2009, H.R. 3590, The Patient Protection and Affordable Health Care Act, and H.R. 3962, Affordable Health Care for America Act, H.R. 4872, the Health Care and Education Reconciliation Act of 2010, as they relate to Medicaid reimbursement for drugs, new fees on manufacturers of drugs and medical devices, and access to IVIG for Medicare beneficiaries.

Client expense: Not reported · Firm income: $57,500

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Medicare reimbursement for IVIG, including provisions in S. 701, The Medicare Patient IVIG Access Act, and HR 1765 related to payments for the furnishing of IVIG in a patient's home for treatment of primary immune deficiency diseases and related proposed amendment to HR 3590, Patient Protection and Affordable Care Act or HR 4872, Health Care and Education Reconciliation Act.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 3200: To provide affordable, quality health care for all Americans and reduce the growth in health care spending. H.R. 4872: The Health Care and Education Reconciliation Act. S. 301: A bill to amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid or SCHIP. H.R.1765: To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. S.701: A bill to amend title XVIII of the Social Security Act to improve access of Medicare beneficiaries to intravenous immune globulins (IVIG). S. 1796/H.R. 3200: America's Healthy Future Act, as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices.

Client expense: $970,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Economic Council (NEC), SENATE, State, Dept of (DOS)

S. 701: Medicare Patient IVIG Access Act of 2009 H.R. 1765: Medicare IVIG Home Infusion Legislation H.R .2002: Medicare Patient IVIG Access Act H.R. 3590: Patient Protection and Affordable Care Act (Medicaid Drug Rebate, 340B Program, Pharmaceutical industry annual fee) H.R. 4872: Reconciliation Act of 2010 (Medicaid Drug Rebate, 340B Program, Pharmaceutical industry annual fee)

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 1765: Medicare IVIG Home Infusion Legislation H.R. 1392: Medicare Part B Prompt-Pay Legislation S. 701: "Medicare Patient IVIG Access Act of 2009" H.R. 2002: Medicare Patient IVIG Access Act

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Medicare/Part B Premium Hold Harmless. H.R. 3631: Provisions extending the current "hold harmless" policy to all Medicare enrollees to ensure 2010 Part B monthly premiums remain at the current rate. Comprehensive Health Care Reform. P.L. 111-148, P.L. 111-152, H.R. 4872, H.R. 3590: provisions related to reducing Medicare Advantage plan payments, reducing the coverage gap in Part D, requiring wealthier Medicare beneficiaries to pay a greater share of the cost of their premiums under Medicare Parts B and D, permitting the Department of Health and Human Services to negotiate drug prices for the Part D program, simplifying plan benefit designs under Part C, expanding benefits for low-income beneficiaries under the Medicare Savings Programs and the Part D Low-Income Subsidy (LIS), improving the process for reassigning LIS beneficiaries to new plans, expanding coverage of prevention services establishing a Medicare Commission, providing expanded Medicaid coverage for home and community-based services, expanding Medicaid coverage of attendant and other home services and supports, establishing a new national insurance program for long-term supports and services, authorizing funding to provide language services to limited English proficiency beneficiaries, authorizing the collection of data regarding disparities in the provision of care, providing safeguards and subsidies to assure affordability of health coverage for seniors, preserving state benefit laws and requirements, reducing permitted age rating ratio for insurance premiums, inclusion of patient-centered quality reporting requirements for providers, creating new claims reviews processes and provider certification, requiring reporting by practitioners of gifts received from pharmaceutical and medical device manufacturers. Medicare/Commission. P.L. 111-148, P.L. 111-152, H.R. 4872: creating an independent commission authorized to establish Medicare payment and policy designed to reduce Medicare spending growth. Medicare/Prescription Drug Plan. S. 330, H.R. 684: authorizing the establishment of a Medicare-operated prescription drug plan; S. 266: authorizing the Secretary of Health and Human Services to negotiate lower prescription drug prices. Medicare/Part D Generics. S. 75: requiring the use of generics where available unless the brand name drug is determined to be medically necessary. Medicare/Part D cost-sharing. S. 1630: establishing limits on required beneficiary cost-sharing under Part D drug plans. Medicare/Part D dual eligibles. P.L. 111-148, P.L. 111-152, H.R. 4872, S. 1634: removing enrollment barriers for low-income beneficiaries and establishing a Medicare-operated prescription drug plan. Medicare/Combating Waste, Fraud, Abuse. P.L. 111-148, P.L. 111-152, H.R. 4872, H.R. 27: relating to provisions to combat waste, fraud, and abuse within Medicare; H.R. 203: increasing civil and criminal penalties for acts involving fraud and abuse and increasing the surety bond amount for suppliers of durable medical equipment. Medicare/Therapy Caps. P.L. 111-148, P.L. 111-152, H.R. 4872, H.R. 3590, H.R. 43, S. 46: repealing or extending exceptions to outpatient rehabilitation therapy caps. Medicare/Private Contracts. H.R. 164: prohibiting denial of Social Security benefits to persons who elect not to participate in Medicare. Medicare/Hearing Coverage. H.R. 504: authorizing coverage of hearing aids and auditory rehabilitation services under Medicare Part B. Medicare/Dental Coverage. H.R. 870: authorizing coverage under Part B for medically necessary dental procedures. Medicare/Rural Improvements. H.R. 902/S. 382: provision authorizing improvements to services provided to beneficiaries residing in rural areas. Medicare/Shingles Vaccine. H.R. 1038: extending Part B coverage to the shingles vaccine. Medicare/Home Health. H.R. 1094: authorizing home health care agencies to assign the most appropriate skilled service to make the initial assessment visit under a Medicare home health plan of care for rehabilitation services. Medicare/Health Care Vouchers. H.R. 1118: authorizing Medicare-eligible seniors to elect to receive vouchers for a health savings account, premiums for a high deductible health insurance plan, or both, in lieu of regular Medicare benefits and suspending Medicare late enrollment penalties between ages 65 and 70. Medicare/Skilled Nursing Facilities. H.R. 1125, S. 647: provisions related to requiring the reporting of expenditures for nursing services at skilled nursing facilities and requiring disclosure of corporate ownership. Medicare/Prevention. H.R. 1213: provisions authorizing ultrasound screening for abdominal aortic aneurysms to at-risk Medicare beneficiaries between the ages of 65 and 75 without the requirement of a prior initial preventive physical examination; H.R. 1894, S. 769: expanding access to bone mass measurement benefits under Part B. Medicare/Part B Drug Payments. P.L. 111-148, P.L. 111-152, H.R. 4872, H.R. 3590, H.R. 1392: relating to appropriate Part B payment amounts for drugs and biologicals. Medicare/Low Income Prescription Drug Benefits. P.L. 111-148, P.L. 111-152, H.R. 4872, H.R. 3590, H.R. 1407, S. 534: authorizing a reduction in cost-sharing under Part D for non-institutionalized, full-benefit dual eligible individuals. Medicare/Disability Benefits. S. 700, H.R. 1708, H.R. 2881: phasing-out the 24-month waiting period for disabled individuals to become eligible for Medicare benefits and eliminating the waiting period for individuals with life-threatening conditions. Medicare/Prescription Drugs for kidney transplants. H.R. 1458, S. 565: provision related to continued coverage for immunosuppressive drugs furnished to beneficiaries that have received kidney transplants and whose entitlement to coverage would otherwise expire. Medicare/Intravenous Drugs. H.R. 1765, S.701: relating to the payment for intravenous immune globulin (IVIG) for the treatment of primary immune deficiency diseases in a patient's home and for certain disposable pumps as durable medical equipment in place of non-disposable pumps. Medicare/Home Infusion Therapy. H.R. 574, S.254: extending Medicare coverage to home infusion therapy. Medicare/Physical Therapy Services. H.R. 1829: authorizing physical therapists to evaluate and treat Medicare beneficiaries without physician referral. Medicare/Part D Premiums. H.R. 1832: limiting Part D premium increases to no more than the Social Security cost-of-living adjustment and requiring the Secretary of Health and Human Services to negotiate lower prescription drug prices. Medicare/Cancer Hospice and Palliative Care. H.R. 1844: provisions authorizing coverage of comprehensive cancer care planning, establishing a Medicare hospice care demonstration, and authorizing grant programs for cancer palliative care and symptom management, provider education, and related research. Medicare/Hospice and Advanced Care Planning. S. 1150, H.R. 2911: provisions related to changing hospice payments and providing advance care planning resources. Medicare/Physician-Manufacturer Transparency. P.L. 111-148, P.L. 111-152, H.R. 4872, H.R. 3590, S. 301: increasing the transparency of the relationship between physicians and the manufacturers of drugs, devices, biologicals, and medical supplies. Medicare/Care Coordination Services. P.L. 111-148, P.L. 111-152, H.R. 4872, H.R. 3590, S. 1131, H.R. 2560: provisions establishing pilot care coordination programs. Medicaid/Home and Community-based Long Term Care. P.L. 111-148, P.L. 111-152, H.R. 4872, H.R. 3590, S. 434, S.1257, H.R. 28552: provisions to remove barriers to providing home and community-based services including providing a state option to provide home and community-based services to individuals for whom such services are likely to prevent, delay, or decrease the likelihood of an individual's need for institutionalized care and authorizing the implementation of assistance grants for states electing to provide home and community-based services under Medicaid; provisions to provide a single point of entry to long term services; provisions to support nursing home diversion programs. Medicaid/Community-based Attendant Services and Supports. P.L. 111-148, P.L. 111-152, H.R. 4872, H.R. 3590, S. 683, H.R. 1670: authorizing coverage of community-based attendant services and supports under Medicaid, increasing funding and establishing a demonstration program for beneficiaries dually eligible for Medicare and Medicaid. P.L. 110-275, P.L. 108-173: implementation of regulations and guidance relating to beneficiary eligibility, enrollment, and effectiveness of exceptions and appeals processes under Medicare Parts C and D.

Client expense: $350,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Medicare Patient IVIG Access Act (S. 701); H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, Health Care and Education Reconciliation Act, provisions concerning Medicaid rebates, orphan drugs; H.R. 4813, to provide for insurance reform, provisions concerning Medicaid rebates, orphan drugs.

Client expense: $60,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

S. 701, "Medicare Patient IVIG Access Act of 2009" H.R. 1765, Medicare IVIG Home Infusion Legislation H.R. 1085 / S. 442 "Health Insurance Coverage Protection Act" Follow-on Biologics Legislation Medicaid Drug Rebate/Health Care Reform

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE

Medicare Patient IVIG Access Act (S.701) Meidcaid Rebate Patient Protection and Affordable Care Act, particularly provisions relating to capture drugs medicaid relates and drug fees.

Client expense: Not reported · Firm income: $30,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

S.701/HR. 2002 the Medicare Patient IVIG Access Act of 2009 Section 4, provisions relating to coverage of home administration of IVIG and reimbursement for services, supplies and equipment. Pharmacy enhancements for consideration to the Medicare Modernization Act no specific legislation. HR. 1765 all provisions, regarding amending the Social Security Act with respect to payment for items and services relating to the furnishing of IVIG in a patients home for the treatment of primary immune deficiency disease and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare program. HR. 203 the Medicare Fraud Prevention Act of 2009 Section 4 provisions relating to the increased surety bond requirement of suppliers of durable medical equipment. S. 956/HR 1970 the Preserve Patient Access to Reputable DMEPOS Providers Act of 2009 all provisions; regarding exempting unsanctioned State-licensed retail pharmacies from the surety bond requirement under the Medicare Program for suppliers of durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS). HR 574/S. 254 the Medicare Home Infusion Therapy Act of 2009 all provisions; regarding amending the Social Security Act to provide for the coverage of home infusion therapy under the Medicare program. HR. 3108 the Medication Therapy Management Benefits Act of 2009, all provisions; regarding amending part D of title XVIII of the Social Security Act to promote medication therapy management under the Medicare part D prescription drug program. HR. 3663 all provisions; regarding amending title XVIII of the Social Security Act to delay the date on which the accreditation requirement under the Medicare Program applies to suppliers of durable medical equipment that are pharmacies.

Client expense: $430,000 · Firm income: Not reported

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE

Medicare and Medicaid reimbursement issues for certain drugs and biologicals; all issues related to Medicare coverage of pre-ESRD education. S. 701, Medicare IVIG Access Act as it relates to Medicare coverage of IVIG services. H.R. 1765, as it relates to Medicare coverage and payment for IVIG administered in the home. H.R. 3200, America's Affordable Health Choices Act of 2009, H.R. 3590, The Patient Protection and Affordable Health Care Act, and H.R. 3962, Affordable Health Care for America Act, as they relate to fees on manufacturers of drugs & medical devices, Medicaid rebates, Medicare reimbursement for drugs & access to IVIG for Medicare beneficiaries, and taxation of employer-sponsored health coverage. S. 525, S. 1232 / H.R. 1298, the Pharmaceutical Market Access & Drug Safety Act, as it relates to the importation of biologicals and pedigree. H.R. 759, the FDA Globalization Act, as it relates to drug safety and pedigree.

Client expense: Not reported · Firm income: $57,500

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Medicare and Medicaid reimbursement issues for certain drugs and biologicals; all issues related to Medicare coverage of pre-ESRD education. S. 701, Medicare IVIG Access Act as it relates to Medicare coverage of IVIG services. H.R. 1765, as it relates to Medicare coverage & payment for IVIG administered in the home. H.R. 3200, America's Affordable Health Choices Act of 2009, H.R. 3590, The Patient Protection and Affordable Health Care Act, and H.R. 3962, Affordable Health Care for America Act as they relate to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices, and access to IVIG for Medicare beneficiaries.

Client expense: Not reported · Firm income: $57,500

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Medicare reimbursement for IVIG, including provisions in S. 701, The Medicare Patient IVIG Access Act, and HR 1765 related to payments for the furnishing of IVIG in a patient's home for treatment of primary immune deficiency diseases, and related amendments to comprehensive health care reform legislation in the House (HR 3962, Affordable Health Care for America Act) and Senate (HR 3590, Patient Protection and Affordable Care Act)

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 3200: To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. S. 301: A bill to amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid or SCHIP. H.R.1765 : To amend title XVIII of the Social Security Act with respect to payment for the furnishing of intravenous immune globulin (IVIG) in a patient's home for the treatment of primary immune deficiency diseases and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare Program. S.701: A bill to amend title XVIII of the Social Security Act to improve access of Medicare beneficiaries to intravenous immune globulins (IVIG). "America's Healthy Future Act" (unnumbered Senate bill), as it relates to Medicaid reimbursement for drugs and new fees on manufacturers of drugs and medical devices. H.R. 6331 (110th Congress): To amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. In particular, execution of the kidney education and bundling provisions. Product Payment Issues Therapy Payment Issues

Client expense: $1,020,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Economic Council (NEC), SENATE, State, Dept of (DOS)

Medicare/Part B Premium Hold Harmless. H.R. 3631: Provisions extending the current "hold harmless" policy to all Medicare enrollees to ensure 2010 Part B monthly premiums remain at the current rate. Comprehensive Health Care Reform. H.R. 3590, H.R. 3962, H.R. 3200, S. 1679: provisions related to reducing Medicare Advantage plan payments, reducing the coverage gap in Part D, requiring wealthier Medicare beneficiaries to pay a greater share of the cost of their premiums under Medicare Parts B and D, permitting the Department of Health and Human Services to negotiate drug prices for the Part D program, simplifying plan benefit designs under Part C, expanding benefits for low-income beneficiaries under the Medicare Savings Programs and the Part D Low-Income Subsidy (LIS), improving the process for reassigning LIS beneficiaries to new plans, expanding coverage of prevention services establishing a Medicare Commission, providing expanded Medicaid coverage for home and community-based services, expanding Medicaid coverage of attendant and other home services and supports, establishing a new national insurance program for long-term supports and services, authorizing funding to provide language services to limited English proficiency beneficiaries, authorizing the collection of data regarding disparities in the provision of care, providing safeguards and subsidies to assure affordability of health coverage for seniors, preserving state benefit laws and requirements, reducing permitted age rating ratio for insurance premiums, inclusion of patient-centered quality reporting requirements for providers, creating new claims reviews processes and provider certification, requiring reporting by practitioners of gifts received from pharmaceutical and medical device manufacturers. Medicare/Commission. S. 1110 and S. 1380: authorizing an enhanced MedPAC as an executive branch commission with authority to implement Medicare payment and policy designed to reduce Medicare spending growth. Medicare/Prescription Drug Plan. S. 330/H.R. 684: authorizing the establishment of a Medicare-operated prescription drug plan; S. 266: authorizing the Secretary of Health and Human Services to negotiate lower prescription drug prices and to use the savings to reduce the coverage gap. Medicare/Part D Generics. S. 75: requiring the use of generics where available unless the brand name drug is determined to be medically necessary. Medicare/Part D cost-sharing. S. 1630: establishing limits on required beneficiary cost-sharing under Part D drug plans. Medicare/Part D dual eligibles. S. 1634: removing enrollment barriers for low-income beneficiaries and establishing a Medicare-operated prescription drug plan. Medicare/Combating Waste, Fraud, Abuse. H.R. 27: relating to additional provisions to combat waste, fraud, and abuse within Medicare; H.R. 203: increasing civil and criminal penalties for acts involving fraud and abuse and increasing the surety bond amount for suppliers of durable medical equipment. Medicare/Therapy Caps. H.R. 43/S. 46: repealing outpatient rehabilitation therapy caps. Medicare/Private Contracts. H.R. 164: prohibiting denial of Social Security benefits to persons who elect not to participate in Medicare. Medicare/Hearing Coverage. H.R. 504: authorizing coverage of hearing aids and auditory rehabilitation services under Medicare Part B. Medicare/Dental Coverage. H.R. 870: authoring coverage under Part B for medically necessary dental procedures. Medicare/Rural Improvements. H.R. 902/S. 382: provision authorizing improvements to services provided to beneficiaries residing in rural areas. Medicare/Shingles Vaccine. H.R. 1038: extending Part B coverage to the shingles vaccine. Medicare/Home Health. H.R. 1094: authorizing home health care agencies to assign the most appropriate skilled service to make the initial assessment visit under a Medicare home health plan of care for rehabilitation services. Medicare/Health Care Vouchers. H.R. 1118: authorizing Medicare-eligible seniors to elect to receive vouchers for a health savings account, premiums for a high deductible health insurance plan, or both, in lieu of regular Medicare benefits and suspending Medicare late enrollment penalties between ages 65 and 70. Medicare/Skilled Nursing Facilities. H.R. 1125, S. 647: provisions related to requiring the reporting of expenditures for nursing services at skilled nursing facilities and requiring disclosure of corporate ownership. Medicare/Prevention. H.R. 1213: provisions authorizing ultrasound screening for abdominal aortic aneurysms to at-risk Medicare beneficiaries between the ages of 65 and 75 without the requirement of a prior initial preventive physical examination; H.R. 1894/S. 769: expanding access to bone mass measurement benefits under Part B. Medicare/Part B Drug Payments. H.R. 1392: relating to appropriate Part B payment amounts for drugs and biologicals. Medicare/Low Income Prescription Drug Benefits. H.R. 1407/S. 534: authorizing a reduction in cost-sharing under Part D for non-institutionalized, full-benefit dual eligible individuals. Medicare/Disability Benefits. S. 700/H.R. 1708, H.R. 2881: phasing-out the 24-month waiting period for disabled individuals to become eligible for Medicare benefits and eliminating the waiting period for individuals with life-threatening conditions. Medicare/Prescription Drugs for kidney transplants. H.R. 1458/S. 565: provision related to continued coverage for immunosuppressive drugs furnished beneficiaries that have received kidney transplants and whose entitlement to coverage would otherwise expire. Medicare/Intravenous Drugs. H.R. 1765/S.701: relating to the payment for intravenous immune globulin (IVIG) for the treatment of primary immune deficiency diseases in a patient's home and for certain disposable pumps as durable medical equipment in place of non-disposable pumps. Medicare/Home Infusion Therapy. H.R. 574/S.254: extending Medicare coverage to home infusion therapy. Medicare/Physical Therapy Services. H.R. 1829: authorizing physical therapists to evaluate and treat Medicare beneficiaries without physician referral. Medicare/Part D Premiums. H.R. 1832: limiting Part D premium increases to no more than the Social Security cost-of-living adjustment and requiring the Secretary of Health and Human Services to negotiate lower prescription drug prices. Medicare/Cancer Hospice and Palliative Care. H.R. 1844: provisions authorizing coverage of comprehensive cancer care planning, establishing a Medicare hospice care demonstration, and authorizing grant programs for cancer palliative care and symptom management, provider education, and related research. Medicare/Hospice and Advanced Care Planning. S. 1150, H.R. 2911: provisions related to changing hospice payments and providing advance care planning resources. Medicare/Physician-Manufacturer Transparency. S. 301: increasing the transparency of the relationship between physicians and the manufacturers of drugs, devices, biologicals, and medical supplies. Medicare/Care Coordination Services. S. 1131, H.R. 2560: provisions establishing pilot care coordination program.

Client expense: $340,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office

Help develop a strategy to provide a better solution for Medicare reimbursement of physicians who administer Intravenous Immune Globulin, or IVIG, a medication that helps patients suffering from chronic diseases. Specific bills lobbied are Medicare Patient IVIG Access Act of 2009 (H.R. 2002/S. 701) and "Affordable Health Care for America Act (H.R.3962), Patient Protection and Affordable Care Act (H.R.3590), America's Affordable Health Choices Act of 2009 (H.R.3200), Affordable Health Choices Act (S.1679), America's Healthy Future Act of 2009 (S.1796).

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Help develop a strategy to provide a better solution for Medicare reimbursement of physicians who administer Intravenous Immune Globulin, or IVIG, a medication that helps patients suffering from chronic diseases. Specific bills lobbied are Medicare Patient IVIG Access Act of 2009 (H.R. 2002/S. 701) and "Affordable Health Care for America Act (H.R.3962), Patient Protection and Affordable Care Act (H.R.3590), America's Affordable Health Choices Act of 2009 (H.R.3200), Affordable Health Choices Act (S.1679), America's Healthy Future Act of 2009 (S.1796).

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE